

# Florence Brunet-Possenti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8186506/publications.pdf>

Version: 2024-02-01

28  
papers

367  
citations

759233

12  
h-index

839539

18  
g-index

30  
all docs

30  
docs citations

30  
times ranked

576  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence of T-cell antigen losses in mycosis fungoides and CD30-positive cutaneous T-cell lymphoproliferations in a series of 153 patients. <i>Pathology</i> , 2022, 54, 729-737.	0.6	7
2	Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case-control study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1445-1452.	0.9	17
3	Treatment strategies and safety of rechallenge in the setting of immune checkpoint inhibitors-related myositis: a national multicentre study. <i>Rheumatology</i> , 2021, 60, 5753-5764.	1.9	17
4	Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data. <i>Annals of Oncology</i> , 2021, 32, 542-551.	1.2	13
5	Tolerance and Effectiveness of Targeted Therapies in Aged Patients with Metastatic Melanoma. <i>Cancers</i> , 2021, 13, 3042.	3.7	3
6	Lymphomatoid papulosis types D and E: a multicentre series of the French Cutaneous Lymphomas Study Group. <i>Clinical and Experimental Dermatology</i> , 2021, 46, 1441-1451.	1.3	6
7	Cemiplimab for Locally Advanced and Metastatic Cutaneous Squamous-Cell Carcinomas: Real-Life Experience from the French CAREPI Study Group. <i>Cancers</i> , 2021, 13, 3547.	3.7	31
8	Quality of life assessment in French patients with metastatic melanoma in real life. <i>Cancer</i> , 2020, 126, 611-618.	4.1	12
9	Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study. <i>Cancers</i> , 2020, 12, 1666.	3.7	17
10	HAVCR2 mutations are associated with severe hemophagocytic syndrome in subcutaneous panniculitis-like T-cell lymphoma. <i>Blood</i> , 2020, 135, 1058-1061.	1.4	29
11	Does body mass index really predict the response to systemic therapies in metastatic melanoma: A multicenter study from the MelBase French National Cohort?. <i>Journal of Clinical Oncology</i> , 2020, 38, 10031-10031.	1.6	1
12	Cetuximab is efficient and safe in patients with advanced cutaneous squamous cell carcinoma: a retrospective, multicentre study. <i>Oncotarget</i> , 2020, 11, 378-385.	1.8	28
13	Association of Time From Primary Diagnosis to First Distant Relapse of Metastatic Melanoma With Progression of Disease and Survival. <i>JAMA Dermatology</i> , 2019, 155, 673.	4.1	7
14	Presence of anti-EBP 180 and anti-EBP 230 in the cerebrospinal fluid of patients with bullous pemphigoid and neurological disease: is there any intrathecal synthesis?. <i>British Journal of Dermatology</i> , 2019, 181, 828-829.	1.5	7
15	Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort. <i>European Journal of Cancer</i> , 2019, 112, 38-46.	2.8	27
16	Occurrence of Extensive Cutaneous Human Papillomavirus Infection After Initiation of Tofacitinib Therapy. <i>JAMA Dermatology</i> , 2019, 155, 629.	4.1	1
17	Use of Combination Systemic-Intratatumoral HPV Vaccine to Treat Cutaneous Basaloid Squamous Cell Carcinomas. <i>JAMA Dermatology</i> , 2019, 155, 123.	4.1	2
18	Immune checkpoint inhibitor rechallenge in patients with immune-related myositis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e129-e129.	0.9	30

#	ARTICLE	IF	CITATIONS
19	Progression and hyperprogression after anti-PD1 therapy for unresectable stage III or IV melanoma patients.. Journal of Clinical Oncology, 2019, 37, e21021-e21021.	1.6	0
20	Detection of titanium nanoparticles in the hair shafts of a patient with frontal fibrosing alopecia. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e442-e443.	2.4	21
21	Impact of anti-interleukin-17 treatment on cutaneous and genital human papillomavirus infection. British Journal of Dermatology, 2018, 179, 1179-1180.	1.5	5
22	Elderly patientâ€™s tolerance and efficacy for MAP-kinase inhibitors in a French melanoma real-life cohort.. Journal of Clinical Oncology, 2018, 36, e21536-e21536.	1.6	0
23	Central nervous system involvement of primary cutaneous diffuse large Bâ€cell lymphoma, leg type: 13 cases. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e498-e501.	2.4	11
24	Pemphigoid gestationis: a successful preventive treatment by rituximab. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e206-e207.	2.4	22
25	Antiepidermis autoantibodies induced by anti-PD-1 therapy in metastatic melanoma. Melanoma Research, 2016, 26, 540-543.	1.2	10
26	Reply to â€Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and toleranceâ€™ by Funck-Brentano et al.. Annals of Oncology, 2016, 27, 363-364.	1.2	21
27	Kaposi's Sarcoma and Pregnancy: Case Report and Literature Review. Dermatology, 2013, 226, 311-314.	2.1	10
28	Focal Rituximab-Induced Edematous Reaction at Primary Cutaneous Follicle Center Lymphoma Lesions: Case Report and Literature Review. Dermatology, 2011, 223, 200-202.	2.1	12